Glenmark Signs A Deal To Market Cosmo Pharma S Acne Cream In Europe And South Africa

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Glenmark signs a deal to market Cosmo Pharma's acne cream in Europe and South Africa

ri-calendar-2-lineSep 28, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Glenmark Pharmaceuticals stated on Wednesday that its subsidiary has signed distribution and licensing agreements for Winlevi, which is used to treat acne, with Cosmo Pharmaceuticals NV.

 

Glenmark Specialty SA, a Glenmark Pharma subsidiary, will market and distribute Winlevi throughout Europe and South Africa, according to a stock exchange filing.

 

According to the agreements, Glenmark Speciality SA will get exclusive rights to commercialize Winlevi in 15 EU countries and South Africa from Cassiopeia, a subsidiary of Cosmo.

 

Glenmark received rights in 15 EU countries: Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, and Sweden.

 

Cassiopeia will be responsible for Centralized Marketing Authorization (CMA) at the European Medicines Agency (EMA), while Glenmark will be responsible for product registration in South Africa and the United Kingdom.

 

Glenmark Pharmaceuticals, a listed company, said that Cosmo will be the only supplier of the medicine.

 

Cassiopea will receive a $5 million upfront payment, as well as double-digit regulatory and sales milestones and agreed-upon double-digit royalties on net sales.

 

The United States Food and Drug Administration (USFDA) has cleared Winlevi for the treatment of acne in patients aged 12 and up.

 

The market for acne in the EU is predicted to expand from $928.7 million in 2021 to $1,297 million in 2028. Acne affects more than 90% of persons aged 11 to 30 years in Europe, with a high prevalence among teens fueling the market's rise.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions